These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 27569930)

  • 41. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.
    Duvoux C; Roudot-Thoraval F; Decaens T; Pessione F; Badran H; Piardi T; Francoz C; Compagnon P; Vanlemmens C; Dumortier J; Dharancy S; Gugenheim J; Bernard PH; Adam R; Radenne S; Muscari F; Conti F; Hardwigsen J; Pageaux GP; Chazouillères O; Salame E; Hilleret MN; Lebray P; Abergel A; Debette-Gratien M; Kluger MD; Mallat A; Azoulay D; Cherqui D;
    Gastroenterology; 2012 Oct; 143(4):986-94.e3; quiz e14-5. PubMed ID: 22750200
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictive Value of Alpha-fetoprotein in the Survival of Living Donor Liver Transplantation Recipients for Hepatocellular Carcinoma.
    Jiang L; Liao A; Yan L; Li B; Zhu W; Wen T
    Hepatogastroenterology; 2014 May; 61(131):747-51. PubMed ID: 26176068
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Second Hepatectomy Improves Survival in Patients With Microvascular Invasive Hepatocellular Carcinoma Meeting the Milan Criteria.
    Hou YF; Li B; Wei YG; Yang JY; Wen TF; Xu MQ; Yan LV; Chen KF
    Medicine (Baltimore); 2015 Dec; 94(48):e2070. PubMed ID: 26632890
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Factors affecting recurrence and survival after living donor liver transplantation for hepatocellular carcinoma.
    Abdel-Wahab M; Sultan AM; Fathy OM; Salah T; Elshobary MM; Elghawalby NA; Yassen AM; Elsarraf WM; Elsaadany MF; Zalatah K
    Hepatogastroenterology; 2013; 60(128):1847-53. PubMed ID: 24719918
    [TBL] [Abstract][Full Text] [Related]  

  • 45. When to call it off: defining transplant candidacy limits in liver donor liver transplantation for hepatocellular carcinoma.
    Bhatti ABH; Qureshi AI; Tahir R; Dar FS; Khan NY; Zia HH; Riyaz S; Rana A
    BMC Cancer; 2020 Aug; 20(1):754. PubMed ID: 32787864
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion.
    Ye JZ; Chen JZ; Li ZH; Bai T; Chen J; Zhu SL; Li LQ; Wu FX
    World J Gastroenterol; 2017 Nov; 23(41):7415-7424. PubMed ID: 29151695
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcomes of Patients With Poorly Differentiated Hepatocellular Carcinoma After Liver Transplantation.
    Krasnodębski M; Grąt M; Masior Ł; Wronka KM; Grąt K; Stypułkowski J; Bik E; Patkowski W; Krawczyk M
    Transplant Proc; 2016 Jun; 48(5):1713-6. PubMed ID: 27496477
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Younger age and presence of macrovascular invasion were independent significant factors associated with poor disease-free survival in hepatocellular carcinoma patients undergoing living donor liver transplantation.
    Wai CT; Woon WA; Tan YM; Lee KH; Tan KC
    Transplant Proc; 2012 Mar; 44(2):516-9. PubMed ID: 22410059
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience.
    Lee KW; Yi NJ; Suh KS
    Transplantation; 2014 Apr; 97 Suppl 8():S20-3. PubMed ID: 24849825
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
    Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
    J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic Value of Pre-transplantation Serum Alpha-Fetoprotein Levels in Hepatocellular Carcinoma Recurrence.
    Montalvá EM; Cantos M; Boscà A; Rubín A; Vinaixa C; Granero P; Maupoey J; López-Andújar R
    Transplant Proc; 2016 Nov; 48(9):2966-2968. PubMed ID: 27932120
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio.
    Harimoto N; Shirabe K; Nakagawara H; Toshima T; Yamashita Y; Ikegami T; Yoshizumi T; Soejima Y; Ikeda T; Maehara Y
    Transplantation; 2013 Dec; 96(11):1008-12. PubMed ID: 24113512
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic Value and Prediction of Extratumoral Microvascular Invasion for Hepatocellular Carcinoma.
    Nitta H; Allard MA; Sebagh M; Ciacio O; Pittau G; Vibert E; Sa Cunha A; Cherqui D; Castaing D; Bismuth H; Guettier C; Lewin M; Samuel D; Baba H; Adam R
    Ann Surg Oncol; 2019 Aug; 26(8):2568-2576. PubMed ID: 31054040
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Benefit of Treating Hepatocellular Carcinoma Recurrence after Liver Transplantation and Analysis of Prognostic Factors for Survival in a Large Euro-American Series.
    Sapisochin G; Goldaracena N; Astete S; Laurence JM; Davidson D; Rafael E; Castells L; Sandroussi C; Bilbao I; Dopazo C; Grant DR; Lázaro JL; Caralt M; Ghanekar A; McGilvray ID; Lilly L; Cattral MS; Selzner M; Charco R; Greig PD
    Ann Surg Oncol; 2015 Jul; 22(7):2286-94. PubMed ID: 25472651
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors.
    Sumie S; Kuromatsu R; Okuda K; Ando E; Takata A; Fukushima N; Watanabe Y; Kojiro M; Sata M
    Ann Surg Oncol; 2008 May; 15(5):1375-82. PubMed ID: 18324443
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic role of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma undergoing liver transplantation.
    Zhang W; Kim R; Quintini C; Hashimoto K; Fujiki M; Diago T; Eghtesad B; Miller C; Fung J; Tan A; Menon KV; Aucejo F
    Liver Transpl; 2015 Jan; 21(1):101-11. PubMed ID: 25283528
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Significance of preoperative fluorodeoxyglucose-positron emission tomography in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients: a Japanese multicenter study.
    Takada Y; Kaido T; Shirabe K; Nagano H; Egawa H; Sugawara Y; Taketomi A; Takahara T; Wakabayashi G; Nakanishi C; Kawagishi N; Kenjo A; Gotoh M; Toyoki Y; Hakamada K; Ohtsuka M; Akamatsu N; Kokudo N; Takeda K; Endo I; Takamura H; Okajima H; Wada H; Kubo S; Kuramitsu K; Ku Y; Ishiyama K; Ohdan H; Ito E; Maehara Y; Honda M; Inomata Y; Furukawa H; Uemoto S; Yamaue H; Miyazaki M; Takada T;
    J Hepatobiliary Pancreat Sci; 2017 Jan; 24(1):49-57. PubMed ID: 27806426
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation.
    Hong G; Suh KS; Suh SW; Yoo T; Kim H; Park MS; Choi Y; Paeng JC; Yi NJ; Lee KW
    J Hepatol; 2016 Apr; 64(4):852-9. PubMed ID: 26658686
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk factors for early recurrence of HBV-related hepatocellular carcinoma meeting milan criteria after curative resection.
    Zhu WJ; Huang CY; Li C; Peng W; Wen TF; Yan LN; Li B; Wang WT; Xu MQ; Yang JY; Jiang L
    Asian Pac J Cancer Prev; 2013; 14(12):7101-6. PubMed ID: 24460258
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences.
    Zheng SS; Xu X; Wu J; Chen J; Wang WL; Zhang M; Liang TB; Wu LM
    Transplantation; 2008 Jun; 85(12):1726-32. PubMed ID: 18580463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.